Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 468

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 8
Chunk 468
---
   315,473          Stockholders’ Deficit        Preferred stock: 25,000,000 authorized; $0.001 par value; no shares issued and outstanding  -   - Common stock: 100,000,000 authorized; $0.001 par value; 60,042,000 shares issued and outstanding  60,042   60,042 Additional paid-in capital  32,302,781   32,298,442 Accumulated deficit  (32,657,795)  (32,615,498)Total Stockholders’ Deficit  (294,972)  (257,014)         TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $31,974  $58,459 

The accompanying notes are an integral part of these financial statements.

 F-3Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Operations

  Year ended   December 31,   2024  2023        Revenues $-  $-          Operating expenses        Selling, general and administrative  37,958   3,517,542 Research and development  -   4,794,825 Provision for doubtful accounts  -   480,000 Provision for purchase deposit write-off  -   12,000 Total operating expenses  37,958   8,804,367          Loss from operations  (37,958)  (8,804,367)         Other expense        Interest expense - related parties  4,339   3,206 Total other expenses  4,339   3,206          Loss before income tax expense  (42,297)  (8,807,573)Income tax expense  -   - Net loss $(42,297) $(8,807,573)         Basic and diluted loss per share of common stock $(0.00) $(0.15)         Weighted average number of shares of common stock outstanding  60,042,000   60,042,000 

The accompanying notes are an integral part of these financial statements.

 F-4Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements